The fast and reliable processing of medical images is of paramount importance to adequately generate data to feed machine learning algorithms that can prevent and diagnose health issues. Here we benchmark different compressed sensing techniques applied to magnetic resonance imaging as a means to reduce the acquisition time spent in the collection of data and signals that form the image. We show that by using these techniques, it is possible to reduce the number of signals needed and, therefore, substantially decrease the time to acquire the measurements. To this end, we have considered and compared different algorithms: the Iterative Re-Weighted Least Squares, the Iterative Soft Thresholding Algorithm, the Iterative Hard Thresholding Algorithm, the Primal Dual Algorithm and the Log-Barrier Algorithm. We have implemented such algorithms in different analysis programs that have been used to perform the reconstruction of the images and found that the Iterative Soft Thresholding Algorithm gives the optimal results. We found that the images obtained with this algorithm have less quality than the original ones, but the quality is good enough to distinguish each body structure and detect any health problems.

Artificial intelligence methods may help in unveliling information hidden in high-dimensional oncological data. Flow cytometry studies of haematological malignancies provide quantitative data with the potential to be used for the construction of response biomarkers. Many computational methods from the bioinformatics toolbox can be applied to these data but have not been exploited in their full potential in leukaemias, specifically for the case of childhood B-cell acute lymphoblastic leukemia. In this paper we analysed flow cytometry data obtained on diagnosis from 54 paediatric B-cell acute lymphoblastic leukemia patients from two local institutions. We constructed classifiers based on the Fisher’s Ratio to quantify differences in expression levels of immunophenotypical markers between patients with relapsing and non-relapsing disease. The distribution of the marker CD38 was found and validated to have a strong discriminating power between both patient cohorts, thus providing a classifier.